Friday, March 21, 2025
spot_img

Danske Bank A/S, transactions by persons discharging managerial responsibilities

20 March 2025

Notification no. 17/2025

Transactions made by persons obliged to report transactions to the Danish FSA and Nasdaq Copenhagen, cf. the EU Market Abuse Regulation.

For further details, please find the attached template for notifications and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

The notifications relates to conditional shares granted to members of the Executive Leadership Team, as part of performance-based remuneration for previous financial years, which have been transferred to their respective accounts.

Danske Bank

Contact: Stefan Kailay Wind, Head of Press Relations, tel. +45 45 14 14 00

Attachments

  • Appendix – Carsten Egeriis – transferred
  • Appendix – Magnus Agustsson – transferred
  • Appendix – Joachim Alpen – transferred
  • Appendix – Christian Bornfeld – transferred
  • Appendix – Karsten Breum – transferred
  • Appendix – Johanna Norberg – transferred

Powered by SlickText.com

Hot this week

CPS Announces $65.0 Million Securitization of Residual Interests

LAS VEGAS, Nevada, March 20, 2025 (GLOBE...

Xcel Energy to Deploy Advanced Virtual Power Plant in Colorado with Itron and Tesla

Integration of Itron's IntelliFLEX Aggregator DERMS Solution and Tesla...

ATN Board Declares Quarterly Dividend

BEVERLY, Mass., March 20, 2025 (GLOBE NEWSWIRE)...

Topics

Xcel Energy to Deploy Advanced Virtual Power Plant in Colorado with Itron and Tesla

Integration of Itron's IntelliFLEX Aggregator DERMS Solution and Tesla...

ATN Board Declares Quarterly Dividend

BEVERLY, Mass., March 20, 2025 (GLOBE NEWSWIRE)...

Credit Acceptance Named 2025 Top Workplaces USA Award Winner

Southfield, Michigan, March 20, 2025 (GLOBE NEWSWIRE)...

MacroGenics Provides Update on Corporate Progress and 2024 Financial Results

Fully enrolled LORIKEET, a randomized 150-patient Phase 2 study...

Skye Bioscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Enrollment completed in Phase 2a CBeyond™ trial of CB1 inhibitor,...
spot_img

Related Articles

Popular Categories

spot_img